SLC5A2 and metabolic dysfunction-associated steatohepatitis: Overall, SGLT-2 inhibitors have shown promise in the treatment of nonalcoholic steatohepatitis (NASH) [43] and metabolic-associated fatty liver disease (MAFLD) [40,43].